靶向KRAS治疗肺腺癌研究进展  

Research progress in the treatment of targeting KRAS in lung adenocarcinoma

作　　者：李敏 鲍宇 柳辉 张素花 LI Min;BAO Yu;LIU Hui;ZHANG Su-hua(Hebei University of Technology,Faculty of Science,Institute of Biophysics,Tianjin 300401,China)

机构地区：[1]河北工业大学理学院生物物理研究所,天津300401

出　　处：《生物技术》2022年第6期796-803,共8页Biotechnology

基　　金：国家自然科学基金重点项目(11735006)。

摘　　要：KRAS是一种致癌驱动因子,它的突变能促进肿瘤细胞增殖,诱发肿瘤产生。KRAS突变是肺腺癌中最常见的突变,存在KRAS基因突变的肺腺癌患者数量占肺腺癌患者数的30%左右,这表明它可能是肺癌潜在的治疗靶点。近年来,针对存在KRAS突变的肺腺癌治疗进行了广泛的研究。该文首先对KRAS的分子结构、生物学功能及其在肺腺癌中的主要突变进行了阐述,然后综述了直接靶向和间接靶向KRAS突变体的肺癌治疗方案,这对于肺癌治疗候选药物的确定,评估新的靶向药物和组合,为肺癌患者提供量身定制的治疗方案具有重要意义。The KRAS gene is one of the most common oncogenes and its mutations can promote tumor cell proliferation and induce tumor production.KRAS mutations are the most frequently oncogene aberrations in lung adenocarcinoma and the ratio of the mutation of KRAS over all mutation in lung adenocarcinoma is about 30%,which indicates that KRAS may represent a potential therapeutic target.The treatment of lung adenocarcinoma with KRAS mutations has been extensively studied in recent years.This article elaborates on the structure,biological functions and the main mutations of KRAS first,then summarizes treatment strategies in lung adenocarcinoma directly and indirectly targeting KRAS mutants.This is very helpful to determine potential candidates,to evaluate novel targeted agents and combinations and make a tailored treatment for patients.

关 键 词：KRAS 肺腺癌 基因突变 靶向治疗 

分 类 号：Q786[生物学—分子生物学]